Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLL442
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
CLL442 is a small molecule topical drug developed by Novartis for the treatment of cutaneous squamous cell carcinoma in situ (SCCis). It is formulated as a cream and was investigated in phase 1/2 trials for safety, tolerability, and efficacy when applied twice daily to lesions. Mechanistically, CLL442 acts as an inhibitor of phosphatidylinositol 3 kinase alpha (PI3Kα) and the serine/threonine-protein kinase mTOR, targeting the PI3K/mTOR signaling pathway, which plays a role in cell growth and proliferation. Phase 1/2 clinical studies concluded that while CLL442 was safe and well tolerated, it did not meet primary efficacy endpoints for lesion reduction or clearance in SCCis.
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on CLL442.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLL442.